Work

Ifosfamide, carboplatin, etoposide with or without bortezomib in patients with relapsed/refractory Hodgkin lymphoma: results of a randomized phase II trial

Year: 2015

Type: article

Abstract: Despite the innumerable successes in curing patients with Hodgkin Lymphoma (HL) in the front-line setting still up to 20% of patients will experience relapsed or refractory disease. Salvage chemoth...

Source: Leukemia & lymphoma/Leukemia and lymphoma

DOI: 10.3109/10428194.2015.1032966

Authors: Meghan Karuturi, Anas Younes, Luis Fayad, Larry Kwak, Barbara Pro, Jatin Shah, Yasuhiro Oki, Rinata Simien, Mary Joy Liboon, Toni Hutto, Lei Feng, Sandra Horowitz, Yago Nieto, Paolo Anderlini, Amin Alousi, Uday Popat, L. Jeffrey Medeiros, Roberto Miranda, Michelle Fanale

Institutions: The University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, Thomas Jefferson University, Thomas Jefferson University Hospital

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funder: National Cancer Institute

Awards: Cancer Center Support Grant, Cancer Center Support Grant

OpenAlex ID: W2155701173

FWCI: 1.32

Cites: 13

Cited by: 9

Related to: 10